Company / Depreciation & Amortization
Astria Therapeutics, Inc. Depreciation & Amortization History
FY2015-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$26.0K
FY2019
5-year range
-
FY2015-FY2019
Trend
-78.2%
vs FY2018
Sector context
#167 of 168
Health Care
What the data says
Among 168 Health Care companies, Astria Therapeutics, Inc. is in the top 1% for depreciation & amortization. Depreciation & Amortization has declined for 3 consecutive years, from $395,000 in FY2016 to $26,000 in FY2019.
Based on SEC 10-K filings.
$26,000 in FY2019 with a 3-year CAGR of -59.6%.
Improved from $304,000 to $26,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -59.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 168This company $26.0K Sector average $212.9M
▼
-100.0% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s depreciation & amortization has declined for 3 consecutive years.
- 3-year CAGR of -59.6%, indicating a declining trend.
- In FY2019, depreciation & amortization decreased 78.2% year-over-year.
- Ranks #167 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $26.0K | -78.2% |
| FY2018 | $119.0K | -60.9% |
| FY2017 | $304.0K | -23.0% |
| FY2016 | $395.0K | +95.5% |
| FY2015 | $202.0K | -18.5% |
As of FY2019 · SEC 10-K · Updated Feb 28, 2026